Ironshore Pharmaceuticals And CHADD To Raise Awareness About The Negative Impact Of ADHD During The Early Morning Routine
GEORGE TOWN, Grand Cayman--(BUSINESS WIRE)--Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc., and Children and Adults with Attention-Deficit/Hyperactivity Disorder (“CHADD”), a national non-profit organization providing education, advocacy and support for individuals with ADHD, today announced an agreement whereby Ironshore will sponsor advocacy programs designed to educate parents, teachers and physicians about ADHD and the critical importance of recognizing the impact of ADHD during the early morning routine (EMR). Functional impairments related to ADHD during the EMR can have lasting effects throughout the day. Ironshore’s sponsorship will enable CHADD to develop three separate webinars that will provide education to parents and training for physicians and teachers. These webinars will be available on the CHADD website in October, which is ADHD Awareness Month.
“Early morning functional impairments represent an unmet medical need in the treatment of ADHD, and we are delighted to be bringing awareness to this important issue. We are particularly pleased to mark ADHD Awareness Month by developing new resources for the many families with ADHD that we serve.”
According to research published in the Journal of Child and Adolescent Psychopharmacology, 91% of parents reported inadequately controlled ADHD symptoms during the early morning routine.1 Parents described that their child with ADHD was often easily distracted, did not listen and did not follow instructions during this period, which can be characterized as the time from awakening until they arrive at school.1 Inadequately controlled early morning ADHD symptoms and impaired functioning can be attributed to the delayed onset of clinically meaningful efficacy afforded by oral stimulant medications that are dosed subsequent to awakening.1 In an attempt to mitigate these early morning challenges, almost half of the surveyed parents/caregivers had awakened early to administer medication.1 Recognizing the unique difficulties that families affected by ADHD face in the morning, CHADD will be adding strategies and tools to their website that may help to reduce the impact of impaired functioning during what is typically the busiest and most chaotic time of the day for families – the early morning routine.
Additional resources will be available via link to an unbranded educational site sponsored by Ironshore, www.ironshorepharma.com/EMR. The site will be routinely updated with valuable resources, educational content and exclusively licensed assessment tools.
“We recognize Ironshore’s sponsorship of these outreach initiatives as consistent with our mission to improve the lives of people affected by ADHD,” said April Gower, CHADD’s Chief Operations Officer. “Early morning functional impairments represent an unmet medical need in the treatment of ADHD, and we are delighted to be bringing awareness to this important issue. We are particularly pleased to mark ADHD Awareness Month by developing new resources for the many families with ADHD that we serve.”
“We want parents and families to know that they are not alone with their struggles during their early morning routine. Ironshore’s agreement with CHADD will allow for the creation of important educational resources and strategies that could help make mornings more manageable,” said David Lickrish, Ironshore’s Chief Executive Officer. “This sponsorship is the most recent example of our ongoing commitment to the physicians, teachers and parents that work so diligently every day to give patients with ADHD the day that they deserve.”
These resources will be available beginning in the month of October at www.chadd.org.
About Ironshore Pharmaceuticals & Development, Inc.
Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a specialty pharmaceutical company that is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.
About CHADD
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), is a national non-profit, tax-exempt [Section 501(c)(3)] organization providing education, advocacy and support for individuals with ADHD. In addition to our informative website, CHADD also publishes a variety of printed materials to keep members and professionals current on research advances, medications and treatments affecting individuals with ADHD. These materials include Attention magazine, Attention weekly, a free electronically mailed current events newsletter, as well as other publications of specific interest to educators, professionals and parents. For more information, please visit: http://www.chadd.org.
1 Sallee FR. Early morning functioning in stimulant-treated children and adolescents with attention-deficit/hyperactivity disorder, and its impact on caregivers. Journal of Child & Adolescent Psychopharmacology. 2015; 25(7):558-565. http://online.liebertpub.com/doi/pdfplus/10.1089/cap.2014.0160
Forward-Looking Statements
This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise